Europese Unie - IJslands - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf - ibandronate sodium monohydrate - filmuhúðuð tafla - 50 mg

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

serb s.a. - gentamicinum súlfat - vefjalyf - 1,3 mg/cm2

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - acidum ibandronicum mónónatríum - filmuhúðuð tafla - 150 mg

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf - ibandronate sodium monohydrate - filmuhúðuð tafla - 150 mg

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf - acidum ibandronicum mónónatríum - stungulyf, lausn - 3 mg